Cargando…

Gastrointestinal Manifestations in Mucopolysaccharidosis Type III: Review of Death Certificates and the Literature

Background: Mucopolysaccharidosis type III (MPS III, Sanfilippo disease) is a life-limiting recessive lysosomal storage disorder caused by a deficiency in the enzymes involved in degrading glycosaminoglycan heparan sulfate. MPS III is characterized by progressive deterioration of the central nervous...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thomas, Sophie, Ramaswami, Uma, Cleary, Maureen, Yaqub, Medeah, Raebel, Eva M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8509825/ https://www.ncbi.nlm.nih.gov/pubmed/34640463 http://dx.doi.org/10.3390/jcm10194445

Ejemplares similares

Recommendations on clinical trial design for treatment of Mucopolysaccharidosis Type III
por: Ghosh, Arunabha, et al.
Publicado: (2017)

Hip pathologies in mucopolysaccharidosis type III
por: Breyer, Sandra Rafaela, et al.
Publicado: (2021)

Novel therapies for mucopolysaccharidosis type III
por: Seker Yilmaz, Berna, et al.
Publicado: (2020)

Assessment of Sleep in Children with Mucopolysaccharidosis Type III
por: Mahon, Louise Victoria, et al.
Publicado: (2014)

Cognitive development in patients with Mucopolysaccharidosis type III (Sanfilippo syndrome)
por: Valstar, Marlies J, et al.
Publicado: (2011)

An investigation of the middle and late behavioural phenotypes of Mucopolysaccharidosis Type-III
por: Cross, Elaine M, et al.
Publicado: (2014)

Growth charts for patients with Sanfilippo syndrome (Mucopolysaccharidosis type III)
por: Muschol, Nicole M., et al.
Publicado: (2019)

Non-cardiac Manifestations in Adult Patients With Mucopolysaccharidosis
por: Stepien, Karolina M., et al.
Publicado: (2022)

Mucopolysaccharidosis III: Molecular basis and treatment
por: Spahiu, Lidvana, et al.
Publicado: (2021)

Death Certificates
Publicado: (1896)

Certificates of Death
Publicado: (1862)

Clinical overview and treatment options for non-skeletal manifestations of mucopolysaccharidosis type IVA
por: Hendriksz, Christian J., et al.
Publicado: (2012)

Protein Misfolding as an Underlying Molecular Defect in Mucopolysaccharidosis III Type C
por: Feldhammer, Matthew, et al.
Publicado: (2009)

Sleep-related hypermotor epilepsy in a patient with mucopolysaccharidosis type III
por: Abramova, Anna A., et al.
Publicado: (2021)

Natural History and Molecular Characteristics of Korean Patients with Mucopolysaccharidosis Type III
por: Kim, Min-Sun, et al.
Publicado: (2022)

Oral manifestation and root canal therapy of the patient with mucopolysaccharidosis
por: Yoon, Ji-Hye, et al.
Publicado: (2019)

The impact of laronidase treatment in otolaryngological manifestations of patients with mucopolysaccharidosis()
por: Dualibi, Ana Paula Fiuza Funicello, et al.
Publicado: (2015)

Death Certificates and Murder
Publicado: (1890)

The Law as to Death Certificates
Publicado: (1898)

Death Certification and Registration
Publicado: (1907)

The Certification and Registration of Deaths
Publicado: (1909)

The Certificate of the Cause of Death
Publicado: (1916)

Death Certification and Murder
Publicado: (1893)

Certificates of the Cause of Death
Publicado: (1898)

Semantics of Death Certification
por: Leadbeatter, Stephen
Publicado: (1986)

The Giving of Death Certificates
Publicado: (1899)

Mucopolysaccharidosis Type I
por: Kubaski, Francyne, et al.
Publicado: (2020)

Orofacial abnormalities in mucopolysaccharidosis and mucolipidosis type II and III: A systematic review
por: de Bode, Chiel J., et al.
Publicado: (2022)

Orthopedic manifestations in patients with mucopolysaccharidosis type II (Hunter syndrome) enrolled in the Hunter Outcome Survey
por: Link, Bianca, et al.
Publicado: (2010)

Clinical manifestations and treatment of mucopolysaccharidosis type I patients in Latin America as compared with the rest of the world
por: Muñoz-Rojas, María Verónica, et al.
Publicado: (2011)

Clinical manifestations in female carriers of mucopolysaccharidosis type II: a spanish cross-sectional study
por: Guillén-Navarro, Encarna, et al.
Publicado: (2013)

Musculoskeletal manifestations in mucopolysaccharidosis type I (Hurler syndrome) following hematopoietic stem cell transplantation
por: Schmidt, Mona, et al.
Publicado: (2016)

Crosstalk between 2 organelles: Lysosomal storage of heparan sulfate causes mitochondrial defects and neuronal death in mucopolysaccharidosis III type C
por: Pshezhetsky, Alexey V
Publicado: (2015)

Unveiling metabolic remodeling in mucopolysaccharidosis type III through integrative metabolomics and pathway analysis
por: Tebani, Abdellah, et al.
Publicado: (2018)

Attitudes of relatives of mucopolysaccharidosis type III patients toward preconception expanded carrier screening
por: Nijmeijer, Stephanie C. M., et al.
Publicado: (2020)

The Medical Certificate of the Cause of Death
por: Prichard, Augustin
Publicado: (1888)

Unqualified Assistants and Death Certificates
Publicado: (1889)

Death certificate: admitting uncertainty
por: Rocha, Luiz Otávio Savassi
Publicado: (2018)

Quality of death certification in Colombia
por: Cendales, Ricardo, et al.
Publicado: (2018)

Osteoarthropathy in mucopolysaccharidosis type II
por: NASCU, IOANA, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_v85qet5rcnb2acgflcd5q9g6jp